GeneDx's loss exceeded forecasts, and analysts cut sales estimates and price targets. Expected sales growth of 21% yearly through 2027 is a positive, but the lowered estimates point to weaker prospects overall.
The larger-than-expected loss and analysts' cuts to sales estimates and price targets point to weaker expectations for GeneDx. Expected faster sales growth through 2027 is a positive, but it does not erase those lowered estimates.
Follow GeneDx Holdings (WGS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for WGS